Indaptus Therapeutics Inc is trading at $3.70 (5.1% down) in pre-market, extending a period of significant volatility characterized by sharp gains and pullbacks over the last two weeks.
- The current move appears to be driven by typical micro-cap biotech volatility rather than a new fundamental catalyst, as there are no fresh company-specific headlines or analyst calls for the June 22, 2026 session.
- Recent investor focus has been on board and leadership transitions, alongside previous uncertainty regarding the company's financing and strategic options.